Heidelberg secures $20 million in amended royalty financing
Germany’s Heidelberg Pharma (FSE: HPHA) has modified its royalty financing agreement with HealthCare Royalty (HCRx), securing an additional $20 million upfront payment.
The amendment extends the Ladenburg-based firm’s cash runway into 2027 and adjusts milestone payments linked to the approval and sales of its imaging agent TLX250-CDx.
Under the revised terms, the company will receive the $20 million payment immediately. The previously agreed $15 million sales-based milestone for 2025 has been eliminated, and the $75 million payment due upon US Food and Drug Administration approval of TLX250-CDx has been reduced to $70 million.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze